Wednesday, October 23, 2019

DMEMEDS shared post via Reuters: AstraZeneca suffers setback as drug fails in eye cancer

LONDON (Reuters) - AstraZeneca's much anticipated cancer drug pipeline suffered a modest blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for a rare cancer of the eye. [Category: healthNews]

Read More

No comments:

Post a Comment

Subscribe Now: Feed Icon